[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pulmonary-complications\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pulmonary-complications":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,47,88,116,151,180],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100621573","association-of-different-tidal-volumes-and-postoperative-pulmonary-complications-100621573",false,"NCT07372378","Association of Different Tidal Volumes and Postoperative Pulmonary Complications","Association of Various Introperative Tidal Volumes and Postoperative Pulmonary Complications After Video-assisted Thoracic Surgery","Inclusion Criteria:\n\n* Age \\> 50 years.\n* ASA physical status I-II.\n* The cardiopulmonary and other vital organ functions are basically normal, and the patient is able to tolerate surgery.\n* Ariscat score \\> 26.\n* Informed consent has been obtained.\n\nExclusion Criteria:\n\n* Patients who refuse to participate in the clinical trial, or have cognitive impairment or impaired ability to understand and express themselves.\n* ASA physical status ≥ III.\n* Patients with congestive heart failure, severe aortic stenosis, or extensive pleural adhesions.\n* Patients with severe psychiatric disorders or allergy to anesthesia-related medications.\n* Patients with severe organ dysfunction such as the liver or kidney dysfunction.","ALL","51 Years",{"count":19,"type":20},650,"ESTIMATED","7 Days","OBSERVATIONAL","The incidence of lung cancer in China is increasing year by year. Currently, the treatment primarily based on video-assisted thoracoscopic surgery (VATS) is still considered the optimal approach for early-stage non-small cell lung cancer. The widespread application of traditional one-lung ventilation (OLV) technology not only achieves effective lung isolation, but also facilitates exposure of the surgical field during thoracoscopic surgery, making it more convenient for surgeons to operate. However, the occurrence of hypoxemia during one-lung ventilation may pose a risk to patient safety.\n\nOne-lung ventilation can lead to increased intrapulmonary shunt, ventilation\u002Fperfusion (V\u002FQ) mismatch, and ischemic-hypoxic lung injury. Hypoxemia is the major problem during one-lung ventilation. Postoperative pulmonary complications (PPCs) are among the major complications following thoracic and general anesthesia surgeries, including atelectasis, pneumonia, and respiratory failure, which significantly prolong hospital stay and increase mortality.\n\nLow tidal volume lung-protective ventilation strategies have been widely implemented. Additionally, permissive hypercapnia, reducing peak airway pressure to minimize barotrauma, and decreasing FiO₂ all help reduce pulmonary complications.Recently, researchers have focused on optimizing ventilation strategies during OLV, such as using PEEP or low VT ventilation alone or in combination, or exploring different combinations of tidal volume and respiratory frequency under consistent minute ventilation (VE), aiming to balance lung protection and oxygenation, reduce complications, and improve patient outcomes.\n\nHowever, to date, there is still no gold standard tidal volume ventilation strategy for reducing pulmonary complications in patients undergoing lung resection.",[25,26,27,28,29],"Pulmonary Complications","Hypoxemia During Surgery","Thoracic Surgery, Video Assisted","One Lung Ventillation (OLV)","Lung Cancer (Non-Small Cell)",[31,32,33,34],"pulmonary complications","hypoxemia","video-assisted thoracic surgery","one lung ventilation","NOT_YET_RECRUITING","2026-01-19",{"date":38,"type":39},"2026-01-28","ACTUAL",{"date":41,"type":20},"2026-01-20",{"date":43,"type":20},"2029-02-01",{"name":45,"class":46},"First Affiliated Hospital of Zhejiang University","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":56,"conditions":57,"keywords":72,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":87},"100616152","generative-ai-impact-on-rheumatoid-arthritis-complications-diagnosis-100616152","NCT07301892","Generative AI Impact on Rheumatoid Arthritis Complications Diagnosis","Impact of Generative Artificial Intelligence on Diagnosing Rheumatoid Arthritis Complications","Inclusion Criteria:\n\n* Patients with an initial diagnosis of rheumatoid arthritis (RA).\n* All real-world RA inpatients admitted to our department.\n* Admission occurring within the real-world data study period.\n\nExclusion Criteria:\n\n* Patients subsequently confirmed not to have RA during the study.",{"count":55,"type":20},100,"Generative AI (GenAI) based on large language models (LLMs) is expected to improve the diagnosis and treatment of autoimmune diseases. We are studying how GenAI may affect the diagnosis of various complications of rheumatoid arthritis (RA). In a retrospective study using RA patients' EHR records, we will quantify physician adoption of GenAI predictions for RA complications and co-existing diseases. In a prospective observational study, we will assess the feasibility of using GenAI predictions as additional clinical information to help physicians make more complete diagnoses of RA complications and co-existing diseases, including complex, uncommon, or rare conditions.",[58,59,60,61,62,63,25,64,65,66,67,68,69,70,71],"Rheumatoid Arthritis (RA","Osteoporosis","Osteoarthritis","Interstitial Lung Disease","Thyroid Diseases","Cardiovascular Diseases","Sjogren's Syndrome","Liver Disorders","Renal Lesions","Vasculitis","Amyloidosis","Peripheral Neuropathy","Thrombosis","RA Complications",[73,74,75,76],"Rheumatoid Arthritis","generative AI","large language model","Rheumatoid arthritis complications","RECRUITING","2025-12-22",{"date":80,"type":39},"2025-12-24",{"date":82,"type":39},"2025-10-01",{"date":84,"type":20},"2026-06",{"name":86,"class":46},"Guang'anmen Hospital of China Academy of Chinese Medical Sciences",1,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":16,"minAge":95,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":99,"phases":100,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":87},"100611284","effectiveness-of-an-innovative-chest-stabilizer-in-rib-fracture-treatment-impact-on-respiratory-function-complications-and-clinical-outcomes-100611284","NCT07238582","Effectiveness of an Innovative Chest Stabilizer in Rib Fracture Treatment: Impact on Respiratory Function, Complications, and Clinical Outcomes","Effectiveness of an Innovative Chest Stabilizer in the Treatment of Rib Fractures: Impact on Respiratory Function, Complications, and Clinical Outcomes","Inclusion Criteria:\n\nAdults aged 18 to 80 years. Blunt chest trauma with at least three rib fractures confirmed by imaging. Numeric Rating Scale (NRS) pain score ≥ 5 at rest, during deep inspiration, or with movement.\n\nAble to perform spirometry reliably (FVC, FEV1, PEF). Hemodynamically stable and medically suitable for participation. Able and willing to provide informed consent.\n\nExclusion Criteria:\n\nAge younger than 18 or older than 80 years. Penetrating chest trauma. Patients who have undergone surgical rib fixation. Active pneumonia, clinically significant atelectasis, or severe pulmonary infection at admission.\n\nUncontrolled cardiovascular, renal, or hepatic disease. Severe cognitive impairment, psychiatric disorders, or inability to comply with study procedures.\n\nSevere respiratory failure requiring invasive mechanical ventilation. Skin infection, open wounds, or dermatologic conditions preventing stabilizer application.\n\nCoagulopathy or contraindications to external chest compression. Pregnancy. Refusal or inability to give informed consent.","18 Years","80 Years",{"count":98,"type":20},74,"INTERVENTIONAL",[101],"NA","This study aims to evaluate the effectiveness of an innovative, non-invasive chest stabilizer in patients with multiple rib fractures caused by blunt chest trauma. Rib fractures often lead to severe pain, breathing difficulties, and complications such as pneumonia or atelectasis. Participants will be randomly assigned to one of two groups: standard pain management or the new chest stabilizer, which will be used for 10 days.\n\nThe study will assess improvements in pain levels, breathing function (including FVC, FEV1, and PEF), and the occurrence of lung-related complications. Additional outcomes such as hospital stay, patient comfort, and skin reactions related to the device will also be evaluated. The goal of this research is to determine whether the innovative stabilizer can provide safer, more comfortable, and more effective treatment compared with current standard care for rib fracture patients.",[104,105,106,25],"Rib Fractures","Blunt Chest Trauma","Thoracic Injuries","2025-11-16",{"date":109,"type":39},"2025-11-20",{"date":111,"type":20},"2025-12-01",{"date":113,"type":20},"2027-12-01",{"name":115,"class":46},"Caner İşevi, MD",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":124,"sex":16,"minAge":95,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":127,"conditions":128,"keywords":132,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":5},"100562875","the-incidence-of-pulmonary-cardiovascular-and-renal-system-non-communicable-complications-associated-with-the-post-acute-phase-of-the-infection-by-covid-19-100562875","NCT06608849","The Incidence of Pulmonary, Cardiovascular and Renal System Non-communicable Complications Associated With the Post-acute Phase of the Infection by Covid-19","A Non-interventional, Prospective, Cross-sectional Study of the Incidence of Pulmonary, Cardiovascular and Renal System Non-communicable Complications Associated With the Post-acute Phase of the Infection by Sars-Cov-2","POINT","Inclusion Criteria:\n\nGroup A (comparators)\n\n1. Adults (18 years or more) of both genders\n2. Negative history of acute COVID-19\n\nGroup B (patients with ΝΟ dysfunction)\n\n1. Adults (18 years or more) of both genders\n2. History of acute COVID-19 hospitalized or non-hospitalized. All cases appearing from start of the pandemic until the last six months may apply\n3. Absence of any current overt organ dysfunction\n4. Absence of signs of any organ dysfunction during acute COVID-19\n\nGroup C (patients with dysfunctions)\n\n1. Adults (18 years or more) of both genders\n2. History of acute COVID-19 hospitalized or non-hospitalized. All cases appearing from start of the pandemic until the last six months may apply\n3. Presence of signs of organ dysfunction of the lung, the kidneys or the heart during acute COVID-19\n\nExclusion Criteria:\n\nGroup A (comparators)\n\n1. Any other co-existing disorder generating clinical symptoms\n2. Failure to thrive according to the attending physicians\n3. Pregnancy or lactation\n\nGroup B (patients with ΝΟ dysfunction)\n\n1. Any other co-existing disorder generating clinical symptoms\n2. Failure to thrive according to the attending physicians\n3. Pregnancy or lactation\n\nGroup C (patients with dysfunctions)\n\n1. Any other co-existing disorder generating clinical symptoms\n2. Medical history of any of:\n\n   * stage III or IV chronic obstructive pulmonary disease according to the GOLD criteria\n   * pulmonary fibrosis or pulmonary hypertension\n   * stage IV solid tumour malignancy under chemotherapy or radiotherapy\n   * systemic sclerosis\n   * congestive heart failure\n   * stage II, III or IV dyspnoea according to the New York Heart Association classification before the acute COVID-19\n3. Limited chance of survival for at least six months due to co-existing comorbidity(-ies) according to the judgement of the attending physicians\n4. Pregnancy or lactation",true,{"count":126,"type":20},345,"More than 660 million cases of COVID-19 have been reported worldwide, with 183 million cases in the EU alone. In several people, after recovery, the effects of the first waves of COVID-19 persisted beyond the acute phase and increased the risk of chronic multiorgan symptoms and disease. Up to 70% of people affected by COVID-19 showed reduced organ function even four months or more after COVID-19 diagnosis. Such a functional decline is associated with an increased risk of the development of non-communicable diseases (NCDs). Thus, there is an essential need for a better knowledge, tools, clinical guidelines and recommendations that it will make it possible to reduce this overrepresentation of NCDs as a consequence of the post-acute phase (PAP) of COVID-19.\n\nThe overall concept underpinning \"POINT\" is to i) build detailed knowledge on the link between the PAP of COVID-19 caused by previous, current, and future SARS-CoV-2 variants in vaccinated and unvaccinated people, and NCDs, ii) identify robust biomarkers and build predictive tools that help early identification and management of risk of NCDs, and iii) develop guidelines and recommendations for all parts of the healthcare value chain, allowing best prevention and care acknowledging vulnerability. The investigators will focus on the NCDs affecting pulmonary, cardiovascular and renal systems.",[25,129,130,131],"Cardiovascular Complications","Renal Complications","COVID-19",[133,134,135,136,137,138,139,140,141],"Covid-19","SARS-CoV-2","Pulmonary complications","Cardiovascular complications","Renal complications","Post-acute phase","Non communicable diseases","Biomarkers","Prevention","2025-11-14",{"date":144,"type":39},"2025-11-17",{"date":146,"type":39},"2024-12-10",{"date":148,"type":20},"2027-11-04",{"name":150,"class":46},"Hellenic Institute for the Study of Sepsis",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":16,"minAge":95,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":99,"phases":161,"briefSummary":162,"conditions":163,"keywords":166,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":179},"100607747","prevention-of-pulmonary-complications-after-laparoscopic-liver-surgery-100607747","NCT07192575","Prevention of Pulmonary Complications After Laparoscopic Liver Surgery","Enhanced Perioperative Pulmonary Physiotherapy for Prevention of Pulmonary Complications After Laparoscopic Liver Surgery","PREPULCION","Inclusion Criteria\n\n* Patients who undergo elective, laparoscopic surgery of liver\n* Patients who are able to provide informed written consent\n* Patients capable of completing questionnaires at the time of consent\n* Patients compliant in taking in preoperative pulmonary counseling and conducting the exercises\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Emergency surgery\n* Planned open surgery\n* Unwillingness to participate in the follow up assessment\n* No informed consent",{"count":160,"type":20},364,[101],"* Background: Postoperative pulmonary complications (PPCs) are the most common complications after major upper abdominal surgery. PPCs include respiratory infections, severe atelectasis, pleural effusion, bronchospasm, aspiration pneumonitis, pneumothorax, exacerbation of chronic pulmonary condition, and respiratory failure. Although PPC rates are higher after open liver surgery, PPCs still occur in approximately 12-13% of patients undergoing laparoscopic liver surgery. Preoperative respiratory physiotherapy education reduces PPCs after open major abdominal surgery and after laparoscopic colorectal surgery. The aim of this study is to investigate the impact of enhanced perioperative pulmonary physiotherapy on the incidence of PPCs after laparoscopic liver surgery.\n* Methods: A prospective, multicentre, single-blinded, randomized controlled trial will be conducted according to the study protocol at participating centers. A total of 326 patients scheduled for laparoscopic liver surgery will be randomized at a 1:1 ratio into intervention group or standard Enhanced Recovery After Surgery (ERAS) -based perioperative education group. Surgeons\u002F researchers are blinded to the patient allocation. Patients in the intervention group receive preoperative breathing education in a single session and an educational video to guide pulmonary training at home. Pulmonary training lasts for 7 days prior to surgery and for 7 days postoperatively. The training includes deep breathing, and coughing, pursed lip breathing and positive expiratory pressure (PEP) therapy. Patients receive instructions for conducting exercises along with an individual risk assessment at a preoperative ambulatory visit. The exercise session (10min) is to be performed two times daily for total of 14 days. The control group receives standard perioperative breathing education. Primary outcome is the rate of postoperative pulmonary complications within 14 days of operation. Secondary outcomes include 90-day mortality, Clavien-Dindo classified complications, length of hospital stay, intensive care unit (ICU) stay, and hospital costs.\n* Discussion: Little effort is currently put into preventing pulmonary complications after surgery, although PPCs aggravate considerable morbidity and costs to health care system. ERAS Society protocols concentrate mainly on optimizing postoperative recovery. Laparoscopic techniques as such and frequent manipulation of the diaphragm during liver surgery provoke PPCs at a considerable rate. Aim of the study is to present a short-and-easy perioperative pulmonary physiotherapy initiative and evaluate its impact on PPC rate and PPCs ramifications, including direct costs, after laparoscopic liver surgery.",[164,25,165],"Liver Surgery","Laparoscopic Liver Surgery",[167,168,31,169],"liver surgery","prehabilitation","laparoscopic liver surgery","2025-09-21",{"date":172,"type":39},"2025-09-25",{"date":174,"type":39},"2024-09-15",{"date":176,"type":20},"2027-10-15",{"name":178,"class":46},"Oulu University Hospital",5,{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":16,"minAge":95,"maxAge":96,"enrollmentInfo":188,"targetDuration":4,"studyType":99,"phases":190,"briefSummary":191,"conditions":192,"keywords":196,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":87},"100596169","biphasic-positive-airway-pressure-ventilation-versus-flow-controlled-ventilation-in-burn-patients-100596169","NCT07041957","Biphasic Positive Airway Pressure Ventilation Versus Flow-Controlled Ventilation in Burn Patients","Biphasic Positive Airway Pressure Ventilation Versus Flow-Controlled Ventilation in Burn Patients: A Monocentric, Randomized Controlled, Parallel Group Trial","BIFLOWBURN","Inclusion Criteria:\n\n* Body weight ≥ 40 kg\n* Invasive ventilation time ≤ 24 hours before admission to the burn ICU or indication for intubation and invasive ventilation within 48 hours after admission to the burn ICU\n* Estimated (further) invasive ventilation time ≥ 24 hours\n* Intervention start within 48 hours after admission to the burn ICU\n* Establishment of a central venous line and invasive blood pressure monitoring as part of the intensive care therapy before the intervention start\n* Signed informed consent from the participant, legal guardian, next of kin in incompetent patients, or an intensivist in charge and independent from the Trial Management Committee in incompetent patients without a representative of the patients will\n\nExclusion Criteria:\n\n* Participation in another interventional trial\n* Duration of invasive ventilation \\> 24 hours at the time point of admission to the burn ICU\n* Estimated (further) invasive ventilation time \\\u003C 24 hours\n* Patients being treated in the burn ICU for (suspected) severe skin reactions such as Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN)\n* Lack of consent from the participant, legal guardian, next of kin, or intensivist in charge to participate in the study",{"count":189,"type":20},24,[101],"The goal of this clinical trial is to learn if the new ventilation mode flow-controlled ventilation (FCV) is a more protective mode of ventilation for adult patients after severe burn injury. The main question it aims to answer is:\n\nDoes FCV reduce the mechanical power (a key determinant of ventilator-induced lung injury) compared to conventional pressure-controlled ventilation (PCV) during ventilation of patients with burn injury?\n\nResearchers will compare FCV with PCV for up to 70 hours of ventilation to see if the mechanical power is reduced during ventilation of participants being in need of ventilation after severe burn injury.\n\nVentilation of participants will be controlled by either FCV or PCV. Group-specific ventilation will have the following characteristics:\n\n* FCV: Control of airway flows during inspiration and expiration, use of individualized lower and upper airway pressures and no fixed values for the volumes being inspired and expired (tidal volumes)\n* PCV: No control of airway flows during expiration, use of individualized lower airway pressures and upper airway pressures for a fixed tidal volume during each breath (6-8 ml\u002Fkg ideal body weight)\n\nIn total, at least 24 participants in need of ventilation after severe burn injury will be ventilated either with FCV (12 participants) or PCV (12 participants) for up to 70 hours.\n\nDuring ventilation mechanical power is computed according to certain ventilation parameters. Additionally, we evaluate organ functions of the cardiovascular systems, the lungs and other organs during and after the group-specific ventilation.",[193,194,25,195],"Burn Injury","Inhalational Injury","Ventilator-induced Lung Injury (VILI)",[197,198,199,200,201],"Flow-controlled ventilation","Pressure-controlled ventilation","Mechanical Power","Dissipated Energy","Ventilator-induced lung injury","2025-06-18",{"date":204,"type":39},"2025-06-27",{"date":206,"type":20},"2025-07",{"date":208,"type":20},"2028-06",{"name":210,"class":46},"University Hospital Bergmannsheil Bochum"]